Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
axitinib
immunotherapy
lenvatinib
neuroendocrine carcinomas
neuroendocrine neoplasms
neuroendocrine tumors
peptide receptor radionuclide therapy (PRRT)
surufatinib
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
13 Nov 2020
13 Nov 2020
Historique:
received:
11
10
2020
revised:
10
11
2020
accepted:
11
11
2020
entrez:
18
11
2020
pubmed:
19
11
2020
medline:
19
11
2020
Statut:
epublish
Résumé
Treatment options for neuroendocrine tumors (NETs) and carcinomas (NECs) are expanding. Early-phase studies have shown preliminary evidence of the antitumor activity of alpha-emitting peptide receptor radionuclide therapy (PRRT), and novel radiopeptides incorporating somatostatin receptor antagonists (rather than agonists) have been developed. Several tyrosine kinase inhibitors (TKIs) with antiangiogenic potential have been evaluated in patients with NETs, including lenvatinib, axitinib, cabozantinib and pazopanib. Recently, two phase 3 clinical trials have demonstrated the efficacy and safety of surufatinib, an inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, fibroblast growth factor receptor (FGFR)-1 and colony stimulating factor-1 receptor (CSF-1R), in patients with pancreatic and extra-pancreatic NETs. Multiple clinical trials of combination immunotherapy have been recently completed, but interpretation of the results is hampered by small samples sizes and discordant outcomes. This review summarizes recent data on emerging treatments for neuroendocrine neoplasms.
Identifiants
pubmed: 33202931
pii: jcm9113655
doi: 10.3390/jcm9113655
pmc: PMC7696369
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):934-946
pubmed: 31707430
N Engl J Med. 2011 Feb 10;364(6):514-23
pubmed: 21306238
Lancet Oncol. 2020 Nov;21(11):1500-1512
pubmed: 32966811
Neuroendocrinology. 2016;103(3-4):383-401
pubmed: 26338447
Lancet Oncol. 2020 Nov;21(11):1489-1499
pubmed: 32966810
Br J Cancer. 2020 Apr;122(9):1309-1314
pubmed: 32152503
Clin Cancer Res. 2020 Sep 1;26(17):4454-4459
pubmed: 32532787
Cancer. 2020 Jul 1;126(13):3021-3030
pubmed: 32320048
N Engl J Med. 2014 Jul 17;371(3):224-33
pubmed: 25014687
Clin Cancer Res. 2019 Dec 1;25(23):6939-6947
pubmed: 31439583
Neuroendocrinology. 2019;109(2):83-99
pubmed: 30699437
Environ Mol Mutagen. 2017 Jun;58(5):235-263
pubmed: 28485537
Clin Cancer Res. 2020 May 15;26(10):2290-2296
pubmed: 31969335
J Clin Oncol. 2009 Oct 1;27(28):4656-63
pubmed: 19704057
Lancet. 2016 Mar 5;387(10022):968-977
pubmed: 26703889
Expert Opin Drug Metab Toxicol. 2019 Dec;15(12):993-1004
pubmed: 31794273
N Engl J Med. 2011 Feb 10;364(6):501-13
pubmed: 21306237
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2106-19
pubmed: 25070685
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
Clin Cancer Res. 2020 May 1;26(9):2124-2130
pubmed: 31980466
Neuroendocrinology. 2019;108(3):256-264
pubmed: 30352433
Ann Oncol. 2015 Sep;26(9):1987-1993
pubmed: 26063633
Endocr Relat Cancer. 2020 Sep;27(9):R329-R343
pubmed: 32590336
CA Cancer J Clin. 2018 Nov;68(6):471-487
pubmed: 30295930
Clin Cancer Res. 2019 Jun 15;25(12):3486-3494
pubmed: 30833272
Curr Treat Options Oncol. 2020 May 23;21(6):52
pubmed: 32447461
Endocr Relat Cancer. 2016 May;23(5):411-8
pubmed: 27080472
Clin Cancer Res. 2017 Aug 15;23(16):4617-4624
pubmed: 28428192
Cell Cycle. 2007 Feb 1;6(3):364-70
pubmed: 17297293
Mol Cancer Ther. 2019 May;18(5):1012-1021
pubmed: 30926632
Semin Nucl Med. 2019 Sep;49(5):422-437
pubmed: 31470935
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
J Nucl Med. 2018 Jun;59(6):907-908
pubmed: 29602817
Curr Oncol Rep. 2017 Feb;19(2):9
pubmed: 28220446
Clin Cancer Res. 2020 Sep 15;26(18):4785-4794
pubmed: 32591465
J Med Chem. 2019 Mar 14;62(5):2708-2719
pubmed: 30735385
Oncologist. 2020 Feb 11;:
pubmed: 32045050